

Table SI. Chemotherapy agent for each patient's sarcoma and classification by disease of sarcoma and secondary hematological malignancies.

No.	SHM	Topoisomerase II inhibitors		Alkylating agents				Other agents				
		Etoposide	Doxorubicin	Ifosfamide	Dacarbazine	Cisplatin	Carboplatin	Methotrexate	Bleomycin	Vincristine	Gemcitabine	Docetaxel
1	MDS		○	○		○			○			
2	MDS		○	○	○	○				○		
3	MDS											
4	AML		○			○						
5	FL	○	○	○	○		○			○		
6	AML		○	○								
7	AML	○	○	○	○	○	○					
8	ALL	○	○	○		○	○					
9	AML	○	○	○		○	○					
10	AML	○	○	○			○					
11	MM											
12	AML	○	○	○		○	○				○	○
13	CML		○			○						
14	ALL		○	○		○			○			
15	MDS		○			○						
16	MDS	○	○	○		○	○					
17	ALL		○	○								
18	AA	○		○			○					

SHM, secondary hematological malignancy; MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; FL, follicular lymphoma; ALL, acute lymphocytic leukemia; MM, multiple myeloma; CML, chronic myeloid leukemia; AA, aplastic anemia.

Table SII. Subgroup analysis of the incidence of SHMs with prior treatment history.

Parameter	SHM (n=18)	None (n=2,935)	P-value
Previous treatment			<0.001
Surgery (n=1295)	2	1,293	
Surgery and chemotherapy (n=1658)	16	1,642	

SHMs, secondary hematological malignancies.

Table SIII. Reasons for not receiving treatment for SHMs.

Reason	Sarcoma status	SHMs	Reasons for not receiving treatment for SHMs
1	Distant metastasis	MDS	No effective chemotherapeutic plan for refractory metastatic sarcoma cytopenia
2	Distant metastasis	MDS	No effective chemotherapeutic plan for refractory metastatic sarcoma cytopenia
3	NED	MDS	Not require treatment
4	NED	AML	Cytopenia with pneumonia, patient refusal
5	Distant metastasis	AML	No effective chemotherapeutic plan for refractory metastatic sarcoma cytopenia

SHMs, secondary hematological malignancies; MDS, myelodysplastic syndrome; NED, no evidence of disease; AML, acute myeloid leukemia.